B
BillionToOne
The only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level
About BillionToOne
BillionToOne is a biotechnology startup that operates in the healthcare sector, specifically in the field of molecular diagnostics. The company's proprietary technology, known as QCT, has the ability to detect and quantify disease at a single base-pair resolution. This means it can identify the tiniest variations in our DNA, which consists of three billion letters or nucleotides.
Read full description
The company's primary focus is on prenatal screening and oncology testing. Their products, Northstar Select™ and Northstar Response™, are commercially available. Northstar Select™ is used to determine the most suitable first line therapy for patients, while Northstar Response™ monitors the effectiveness of the therapy.
BillionToOne's business model revolves around providing these diagnostic services to healthcare providers. They generate revenue by selling their testing services to these providers, who then use the results to guide their treatment plans.
The company's mission is to make molecular testing more accurate, efficient, and accessible to all. They are driven by a culture of growth, equality, and teamwork, with a strong focus on making a positive impact in healthcare.
The company was founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and is comprised of a team of engineers, scientists, and industry experts who are passionate about improving healthcare through their innovative technology.
At a glance
- Founded
- 2016
- Headquarters
- Menlo Park, United States
- Listing
- IPO 2025
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning BillionToOne.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Y Combinator
Fifty Years
Sanabil Accelerator by 500 Global- PVPacific 8 Ventures
Wei Guo
NewDo Venture
Series A9 investors entered at this stage
Hummingbird Ventures
Neotribe
500 Global
Civilization Ventures
e2vc
HOF Capital
Libertus Capital- FGFour Rivers Group
Norwest Venture Partners
Series B and later6 investors entered at this stage
Adams Street Partners
Baillie Gifford
Time BioVentures
Bridge Bank
Premji Invest
Neuberger Berman
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
17 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about BillionToOne on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BillionToOne on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.